Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=17

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04516746-c0657a71",
        "title": "AZD1222 vs Placebo: Number of Participants With First Post-intervention Response for SARS-CoV-2 Nucleocapsid Antibodies Post Second Dose of Study Intervention",
        "summary": "156 of 17662 against 202 of 8550; risk difference -1.5 points, 95% interval -1.8 to -1.1; NCT04516746, Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",
        "record": "/library/comparisons/NCT04516746-c0657a71",
        "nct_id": "NCT04516746",
        "kind": "outcome",
        "participants": 26212,
        "risk_difference": {
          "value": -0.014793209195941199,
          "lower": -0.018462277083712213,
          "upper": -0.011432718942266284
        },
        "group_1": "156 of 17,662",
        "group_2": "202 of 8,550",
        "difference": "-1.5 points",
        "interval": "-1.8 to -1.1",
        "trial_title": "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults"
      },
      {
        "id": "NCT04516746-e9c9fa82",
        "title": "AZD1222 vs Placebo: Number of Participants With COVID-19 Severe or Critical Symptomatic Illness Post Second Dose of Study Intervention",
        "summary": "0 of 17662 against 8 of 8550; risk difference -0.1 points, 95% interval -0.2 to -0.0; NCT04516746, Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",
        "record": "/library/comparisons/NCT04516746-e9c9fa82",
        "nct_id": "NCT04516746",
        "kind": "outcome",
        "participants": 26212,
        "risk_difference": {
          "value": -0.0009356725146198831,
          "lower": -0.0018453941154686917,
          "upper": -0.00042553535767418367
        },
        "group_1": "0 of 17,662",
        "group_2": "8 of 8,550",
        "difference": "-0.1 points",
        "interval": "-0.2 to -0.0",
        "trial_title": "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=18",
  "request_id": "0P8eUKDIQwLgiv5i"
}